Skip to main content

Table 1 Clinicopathological and genetic characteristics of AA CRC cases

From: Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study

  African Americans     
  All non-MSI-H MSI-H Odds Ratio (95% CI) P
Number of patients 95 66 (69)a 29 (31)a   
Mean Age 65.7+15.0
-
65.2+14.0
-
65.9+17.5
-
  0.84
Gender      0.39
   Female 56 (59) 37 (57) 19 (66) 1  
   Male 39 (41) 29 (43) 10 (34) 0.67(0.27–1.67)  
Site      0.47
   Distal 38 (40) 28 (43) 10 (34) 1  
   Proximal 57 (60) 38 (57) 19 (66) 0.71(0.29–1.77)  
Mucin Production 95     0.15
   None 68 (72) 51(77) 17(58) 1  
   < 50% 15 (15) 9 (14) 6 (21) 2.0(0.62–6.44)  
   > 50% 12 (13) 6 (9) 6(21) 3.0(0.85–10.55)  
Differentiation 90     0.47
   Well 3 (3) 2 (3) 1 (3) 1  
   Moderate 71 (79) 51 (83) 20 (72) 0.64(0.5–8.62)  
   Poor 16 (18) 9 (14) 7 (25) 0.5(0.17–1.54)  
Stage 92     0.59
   Stage 1 8 (9) 7 (11) 1 (3) 1  
   Stage 2 37 (40) 24 (38) 13 (45) 0.67(0.09–4.93)  
   Stage 3 35 (38) 23 (37) 12 (41) 1.08(0.27–4.29)  
   Stage 4 12 (13) 9 (14) 3 (11) 0.8(0.2–3.27)  
BRAF 82     0.00
   wild type 74 (90) 59 (98) 15 (68)   
   V600E 8 (10) 1 (2) 7 (32) 27.5(3.1–241.3)  
hMLH1 methylation (MSP) 70     0.33
   Unmethylation 4 (6) 2 (4) 2 (10) 1  
   Methylation 66 (94) 48 (96) 18 (90) 0.38(0.5–2.87)  
p16 methylation (MSP) 47     0.37
   Unmethylation 28 (60) 14 (54) 14 (67) 1  
   Methylation 19 (40) 12 (46) 7 (33) 0.58(0.18–1.92)  
hMLH1 expression by IHC 76     0.00
   Normal 50 (65) 45 (83) 5 (23) 1  
   Negative 26 (35) 9 (17) 17 (77) 16.67(5–50)  
hMSH2 expression by IHC 74     0.29
   Normal 66 (89) 46 (87) 20 (95) 1  
   Negative 8 (11) 7 (13) 1 (5) 0.33(0.04–2.86)